Welcome to the 2nd Rare CNS & Neurodevelopmental Drug Development Summit
Developing New Outcome Measures, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare, Genetic CNS Disorders
With further clinical data emerging, drug development for rare CNS and neurodevelopmental disorders is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers; catapulting this critical field forwards to change patients’ lives.
The 2nd Rare CNS & Neurodevelopmental Drug Development Summit is the definitive industry-dedicated forum for large pharma, biotech, academia, and patient advocacy groups, paving the way towards symptomatic and successful disease modifying treatments.
Tightly focused on industry progress, join stakeholders exploring ASOs, gene therapies and small molecules across autistic syndromes and seizure phenotypes in at this unique drug sponsor conference.
Don’t miss out on the industry’s definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design, endpoints and delivery and toxicity concerns as well as deep diving into functional & molecular biomarkers, emerging therapeutic targets and translational biology.
If you are working towards treatments for rare CNS and neurodevelopmental disorders, including (but not limited to) Angelman Syndrome, Rett syndrome, Fragile X, Dravet Syndrome & CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics, this is the platform you need.
What’s New In 2022?
Brand new industry insights include:
Navigate pre-clinical research methods to inform translation in the clinic: iPSC Cells, Organoids & Animal Models with Biogen, Ionis & n-Lorem
Explore the development of clinically meaningful outcome measures with Roche, Rett Syndrome Research Trust and LouLou Foundation, to navigate patient centric outcome measures
Dive into molecular, quantitative and functional biomarkers with Biogen, Ultragenyx, FNIH & Anavex Life Science, exploring molecular, quantitative and functional such as sleep, EEG & behaviour
Engage with foundations, trusts and patient advocates to appreciate the power of industry and patient group collaboration
Expert Speakers Include:
Chief Scientific Officer
Foundation for Angelman Syndrome Therapeutics (FAST)
Rush University Medical Center
Vice President Neurology Research
Director & Professor
MIND Institute, Psychiatry and Behavioural Sciences, University of California, Davis
Founder, President & CEO
Ulysses Neuroscience Ltd.
Harvard Medical School
FAXA Research Foundation
Executive Director, Clinical Biomarker Development & Strategy
Chief Executive Officer
“The Neurodevelopmental Drug Development Summit was a fantastic opportunity to share learnings among an outstanding group of academic, industry and patient advocacy experts working toward a common goal of transformative therapies for neurodevelopmental disorders”